On June 4, BeiGene (06160.HK) rose 4.18% in regular trading, trading at 172.3 HKD/share, with trading volume of HKD 144 million.

The stock had previously declined approximately 10% over three consecutive trading sessions, primarily dragged down by Baker Bros. Advisors LP's reduction of approximately USD 190 million in holdings and sustained weakness in the innovative drug sector. On the positive side, BeiGene announced on May 29 that Antaishi (tarlatamab for injection) received NMPA approval for second-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in adult patients who have failed one prior systemic therapy including platinum-based chemotherapy. Clinical data from the DeLLphi-304 study demonstrated a 40% reduction in the risk of death, with median overall survival extended by 5.3 months to 13.6 months compared to standard chemotherapy. The broader biotech sector stabilized on the day, with previously oversold stocks staging a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)